Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline in Rapidly Progressive Glomerulonephritis
NCT00354198Phase 3Terminated
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2006
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pentoxifylline in crescentic glomerulonephritis (RPGN), sponsored by National Taiwan University Hospital. Primary endpoint: Initiation of acute dialysis or doubling of serum creatinine levels at 3 months. Started Aug 2006; status: terminated.
02
Drugs
pentoxifylline
03
Conditions
crescentic glomerulonephritis (RPGN)
Beyond the preview
Go deeper on NCT00354198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354198.